Retargeting T Cells to GD2 Pentasaccharide on Human Tumors Using Bispecific Humanized AntibodyHong Xu, Nai‐Kong V. Cheung, Morgan Huse et al.|Cancer Immunology Research|2014Cited by 97
Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumorsMing Cheng, Nai‐Kong V. Cheung, Brian H. Santich et al.|OncoImmunology|2016Cited by 41